Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 99,392
  • Shares Outstanding, K 50,710
  • Annual Sales, $ 18,720 K
  • Annual Income, $ -30,100 K
  • 36-Month Beta 2.86
  • Price/Sales 5.12
  • Price/Cash Flow 0.00
  • Price/Book 1.80

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.75 +16.57%
on 11/15/17
2.83 -27.92%
on 11/10/17
-0.66 (-24.44%)
since 10/17/17
3-Month
0.93 +119.35%
on 08/29/17
3.75 -45.60%
on 10/12/17
+0.95 (+87.16%)
since 08/17/17
52-Week
0.93 +119.35%
on 08/29/17
3.84 -46.88%
on 03/02/17
+0.83 (+68.60%)
since 11/17/16

Most Recent Stories

More News
Options Traders Expect Huge Moves in Infinity Pharmaceuticals (INFI) Stock

Surging implied volatility makes Infinity Pharmaceuticals (INFI) stock lucrative to the option traders.

INFI : 2.04 (+4.08%)
Today's Research Reports on Stocks to Watch: Infinity Pharmaceuticals and Synergy Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / November 13, 2017 / Both Infinity Pharmaceuticals and Synergy Pharmaceuticals closed in the red on Friday. Shares of Infinity closed down nearly 14% despite encouraging results...

INFI : 2.04 (+4.08%)
SGYP : 1.95 (-2.50%)
Featured Company News - Infinity Shares Clinical and Translational Data from Monotherapy Dose-Escalation Component of Phase-1/1b Study for IPI-549

Research Desk Line-up: Spectrum Pharma Post Earnings Coverage

SPPI : 19.50 (-5.93%)
INFI : 2.04 (+4.08%)
Infinity Pharmaceuticals Reports IPI-549 Clinical and Translational Data from Completed Monotherapy Dose-Escalation Component of Phase 1/1b Clinical Study in Patients with Advanced Solid Tumors at SITC Annual Meeting

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported Phase 1 clinical and translational data for IPI-549, an oral, selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibitor that targets...

INFI : 2.04 (+4.08%)
Technical Reports on Biotech Equities -- ImmunoGen, Incyte, Infinity Pharma, and Insmed

If you want a Stock Review on IMGN, INCY, INFI, or INSM then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Ahead of today's trading session, DailyStockTracker.com...

IMGN : 6.15 (unch)
INCY : 105.47 (-0.95%)
INFI : 2.04 (+4.08%)
INSM : 30.33 (-1.94%)
Infinity (INFI) Q3 Loss Narrower than Expected, View Intact

Infinity Pharmaceuticals (INFI) Q3 loss was narrower than estimates and the year-ago quarter loss.

EXEL : 26.38 (+2.13%)
INFI : 2.04 (+4.08%)
VSTM : 3.43 (-0.87%)
BMY : 61.32 (-0.89%)
Infinity Provides Company Update and Reports Third Quarter 2017 Financial Results

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2017 financial results and provided an update on the company, including its progress with IPI-549, an oral immuno-oncology...

INFI : 2.04 (+4.08%)
Infinity to Host Investor Reception and Webcast at SITC

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it will host a reception for investors and analysts on Friday, November 10, 2017, from 6:00 a.m. to 8:00 a.m. to discuss the clinical...

INFI : 2.04 (+4.08%)
Infinity, Wells Fargo Upgrade, SITC Meeting in November, IPI-549 Update

NEW YORK, NY / ACCESSWIRE / October 23, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

INFI : 2.04 (+4.08%)
Developments in the Cancer Immunotherapy Market

According to data provided by Grand View Research Inc., the global cancer immunotherapy market is expected to reach USD 118.8 billion by 2025. The market is expected to benefit from introduction of newer...

ADXS : 3.19 (-1.54%)
RGBP : 0.0900 (+21.62%)
CRIS : 0.88 (-5.38%)
ONCS : 2.11 (-2.31%)
INFI : 2.04 (+4.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

See More

Key Turning Points

2nd Resistance Point 2.21
1st Resistance Point 2.13
Last Price 2.04
1st Support Level 1.93
2nd Support Level 1.81

See More

52-Week High 3.84
Fibonacci 61.8% 2.73
Fibonacci 50% 2.38
Fibonacci 38.2% 2.04
Last Price 2.04
52-Week Low 0.93

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart